[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL: Management of urethral recurrence after orthotopic urinary diversion. BJU Int; 2010 Jul;106(1):56-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of urethral recurrence after orthotopic urinary diversion.
  • STUDY TYPE: Therapy (case series) Level of Evidence 4 OBJECTIVE To evaluate our experience with urethral recurrences in patients treated by radical cystectomy(RC) and orthotopic neobladder urinary diversion for carcinoma of the bladder.
  • Six patients (2.3%) developed local recurrence of urothelial cancer (UC) within the urethra after this treatment.
  • The median (range) time to presentation with recurrence after RC was 2.4 (0.7-3.6) years for pT1-4 UC.
  • Recurrences were treated with various methods, including transurethral resection, urethrectomy with conversion of neobladder to continent catheterizable diversion, and chemotherapy.
  • CONCLUSIONS: In our experience, local recurrences involving the urethra are infrequent.
  • Neoadjuvant chemotherapy should be considered for recurrences with adverse clinicopathological features.
  • [MeSH-major] Carcinoma, Transitional Cell / surgery. Cystectomy / methods. Neoplasm Recurrence, Local / surgery. Urethral Neoplasms / secondary. Urinary Bladder Neoplasms / surgery. Urinary Diversion / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Treatment Outcome. Urinary Reservoirs, Continent

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20002676.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  •  go-up   go-down


2. Yoshinaga A, Hayashi T, Ishii N, Ohno R, Terao T, Kamata S, Watanabe T, Yamada T: [Vesicorectal fistula caused by pelvic metastasis of penile cancer: a case report]. Hinyokika Kiyo; 2005 Jan;51(1):53-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Vesicorectal fistula caused by pelvic metastasis of penile cancer: a case report].
  • Tumor biopsy revealed squamous cell carcinoma.
  • Although he was given radiation therapy and subcutaneous injection therapy of bleomycin, viable cancer cells remained.
  • Then he was given combination chemotherapy of bleomycin and cisplatin, and paint therapy of bleomycin ointment.
  • Local recurrence with a cauliflower-like tumor occurred five years after the chemotherapy.
  • Computerized tomography of pelvis demonstrated a mass 3 cm in diameter in the anterior portion of anal and cystogram demonstrated a vesicorectal fistula.
  • Then we inserted a urethral catheter, which resulted in obstruction of fistula by its balloon, and we made a cystostomy for securing urinary tract.
  • Pathological examination of tissue around the fistula revealed squamous cell carcinoma.
  • His quality of life was improved, but his general condition became worse gradually and he died of cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15732344.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Seabra D, Faria E, Dauster B, Rodrigues G, Fava G: Critical analysis of salvage radical prostatectomy in the management of radioresistant prostate cancer. Int Braz J Urol; 2009 Jan-Feb;35(1):43-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Critical analysis of salvage radical prostatectomy in the management of radioresistant prostate cancer.
  • PURPOSE: To critically evaluate salvage radical prostatectomy (SRP) in the treatment of patients with recurrent prostate cancer (PCa).
  • The mean prostate specific antigen doubling time (PSA-DT) was 14 months (6-20).
  • Bleeding > 600 mL occurred in 14% of the cases; urethral stenosis in 50%; and urinary incontinence (two or more pads/day) in 72%.
  • The PSA level rose in 9, of which 6 had PSA-DT < 10 months.
  • PSA-DT has shown to be important for the selection and SRP should not be performed if PSA-DT > 10 months.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Prostatectomy / adverse effects. Prostatic Neoplasms / surgery. Salvage Therapy / adverse effects
  • [MeSH-minor] Aged. Dose-Response Relationship, Radiation. Erectile Dysfunction / etiology. Humans. Male. Middle Aged. Neoplasm Staging. Prostate-Specific Antigen / blood. Radiation Tolerance. Treatment Outcome. Urinary Incontinence / etiology

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19254397.001).
  • [ISSN] 1677-6119
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


Advertisement
4. Huncharek M, McGarry R, Kupelnick B: Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res; 2001 Jan-Feb;21(1B):765-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
  • BACKGROUND: The impact of in tranvesical chemotherapy on preventing recurrence of superficial transitional cell carcinoma of the bladder is controversial.
  • The objective of this report is to present a meta-analysis of the available clinical trial data to quantify the effect of intravesical chemotherapy on tumor recurrence following trans-urethral resection (TURB) in patients with recurrent superficial bladder cancer.
  • METHODS: A prospective study protocol outlining a meta-analysis was developed followed by a thorough search of the existing published literature using strict eligibility criteria.
  • The outcome of interest was the proportion of patients with tumor recurrence at one, two and three years post-TURB.
  • RESULTS: Combining all 8 studies using 1 year recurrence as the outcome measure yielded a Peto odds ratio (ORp) of 0.62, demonstrating a 38% reduction in one year recurrence among patients treated with intravesical chemotherapy versus TURB alone.
  • Using 2 and 3 year recurrence as the outcome measure yielded ORp's of 0.46 and 0.35 respectively, favoring TURB + intravesical chemotherapy versus TURB alone.
  • Sensitivity analyses showed that drug type appeared to account for the observed heterogeneity with a stratified analysis demonstrating that adriamycin is less effective in reducing subsequent tumor recurrences than all other drugs studied.
  • CONCLUSION: Intravesical chemotherapy appears to have a major impact on decreasing the chance of recurrence of recurrent superficial bladder cancer.
  • These data are in contrast to prior analyses suggesting only modest efficacy of such treatment in this clinical setting.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Transitional Cell / drug therapy. Neoplasm Recurrence, Local / prevention & control. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Administration, Intravesical. Clinical Trials as Topic. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Epirubicin / administration & dosage. Epirubicin / therapeutic use. Follow-Up Studies. Humans. Mitomycin / administration & dosage. Mitomycin / therapeutic use. Odds Ratio. Prospective Studies. Randomized Controlled Trials as Topic. Teniposide / administration & dosage. Teniposide / therapeutic use. Thiotepa / administration & dosage. Thiotepa / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Transitional cell carcinoma.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. THIO-TEPA .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11299841.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 80168379AG / Doxorubicin; 905Z5W3GKH / Thiotepa; 957E6438QA / Teniposide
  •  go-up   go-down


5. Cresswell J, Roberts JT, Neal DE: Urethral recurrence after radical radiotherapy for bladder cancer. J Urol; 2001 Apr;165(4):1135-7
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urethral recurrence after radical radiotherapy for bladder cancer.
  • PURPOSE: Following cystectomy for bladder cancer, orthotopic reconstruction may result in a decreased risk of urethral recurrence compared to cutaneous diversion.
  • We evaluate the rate of urethral recurrence after radical external beam radiotherapy.
  • Patients treated with chemotherapy were excluded from study.
  • Tumor stages were T1 in 7%, T2 in 41%, T3 in 42% and T4a in 10% of the patients.
  • Urethral recurrence developed in 7 (3.2%) cases and was detected within 18 months (median 10 months, range 3 months to 5 years) of followup in 5.
  • In 2 of these 7 cases recurrence developed in the prostatic urethra, and when these 2 cases were excluded from analysis the recurrence rate decreased to 2.3%.
  • A total of 64 men completed 5-year followup, with a 4.7% rate of urethral recurrence (3.1% excluding prostatic urethral recurrence).
  • Multifocal disease, bladder neck involvement, prostatic disease and cis were possible risk factors for urethral recurrence.
  • CONCLUSIONS: The risk of urethral recurrence after radical radiotherapy for transitional cell carcinoma of the bladder is comparable with that reported after orthotopic reconstruction.
  • [MeSH-major] Carcinoma, Transitional Cell / radiotherapy. Neoplasm Recurrence, Local / prevention & control. Urethral Neoplasms / prevention & control. Urinary Bladder Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cystectomy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Urinary Diversion

  • Genetic Alliance. consumer health - Urethral cancer.
  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11257654.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, Evans A, Scherz A, Savard J, Chin JL, Wilson BC, Elhilali M: Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int; 2008 Aug 5;102(5):556-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses.
  • OBJECTIVE: To report on the efficacy of TOOKAD (WST 09; NegmaLerads, Magny-Les-Hameaux, France) vascular-targeted photodynamic therapy (VTP) as a method of whole-prostate ablation in patients with recurrent localized prostate cancer after the failure of external beam radiotherapy (EBRT).
  • PATIENTS AND METHODS: Patients received a fixed photosensitizer dose of 2 mg/kg and patient-specific light doses as determined by computer-aided treatment planning.
  • The treatment response was assessed by measuring serum prostate-specific antigen (PSA) levels, lesion formation (avascular areas of tissue) measured on 7-day gadolinium-enhanced T1-weighted magnetic resonance imaging (MRI) and a 6-month biopsy.
  • RESULTS: Treatment of the whole prostate was possible with minimal effects on surrounding organs.
  • An increased light dose improved the tissue response, with MRI-detectable avascular lesions, encompassing up to 80% of the prostate in some patients.
  • Side-effects were modest and self-limited in most patients; there were recto-urethral fistulae in two patients, one of which closed spontaneously.
  • [MeSH-major] Bacteriochlorophylls / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / methods. Prostate / pathology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Biopsy / methods. Dose-Response Relationship, Drug. Humans. Magnetic Resonance Imaging. Male. Prostate-Specific Antigen / blood. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18494829.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA33894
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bacteriochlorophylls; 0 / palladium-bacteriopheophorbide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


7. Tsukamoto T, Yonese J, Kin T, Samejima T, Hasegawa Y, Fukui I, Ishikawa Y: [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment]. Nihon Hinyokika Gakkai Zasshi; 2002 Mar;93(3):483-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinoma in situ of the penis rapidly progressing after carbon dioxide laser treatment].
  • Laser treatment is considered to be effective in treating carcinoma in situ of the penis.
  • We, however, report a case with carcinoma in situ of the penis which developed invasive carcinoma and inguinal lymphnode metastases only 6 months after the laser treatment.
  • A physical examination revealed thick erythema, 12 millimeters in diameter, around the external urethral meatus.
  • Although the lesion appeared to slightly extend into the urethra, it was primarily treated with the CO2 laser.
  • Six months after the treatment, however, local recurrence was confirmed by the touch smear cytology, resulting in the partial amputation of the penis.
  • The histopathological examination revealed subepithelial and marked lymphatic invasion of the tumor and positive margin in the urethral stump (squamous cell carcinoma in situ).
  • The patient received adjuvant chemotherapy and has been alive and well without evidence of disease 40 months after the initial treatment.
  • [MeSH-minor] Aged. Disease Progression. Humans. Lymphatic Metastasis. Male. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11968805.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


8. Gillitzer R, Hampel C, Wiesner C, Hadaschik B, Thüroff J: Single-institution experience with primary tumours of the male urethra. BJU Int; 2008 Apr;101(8):964-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-institution experience with primary tumours of the male urethra.
  • OBJECTIVE: To assess primary tumours of the urethra in males.
  • PATIENTS AND METHODS: We retrospectively reviewed our database from 1986 to 2006 for primary tumours of the male urethra; nine patients with primary tumours of the urethra were analysed and follow-up information was obtained.
  • RESULTS: Three patients had tumours of the prostatic urethra, two of which had proliferating focal inflammation and one a low-grade, superficial urothelial cancer.
  • Six patients had carcinoma of the bulbar or penile urethra, including two with previous local percutaneous radiotherapy for prostate cancer.
  • One patient had adjuvant chemotherapy after surgery.
  • CONCLUSION: Primary carcinoma of the male urethra is a rare entity.
  • Local surgical tumour control is essential for long-term survival, but the extent of surgery depends on tumour location and stage.
  • Multimodal therapy might be required to obtain an optimum oncological outcome.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Urethral Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Combined Modality Therapy. Epidemiologic Methods. Humans. Lymphatic Metastasis. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18070169.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Dimarco DS, Dimarco CS, Zincke H, Webb MJ, Bass SE, Slezak JM, Lightner DJ: Surgical treatment for local control of female urethral carcinoma. Urol Oncol; 2004 Sep-Oct;22(5):404-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment for local control of female urethral carcinoma.
  • We reviewed 53 patients (mean age 63 years) who underwent partial urethrectomy (n = 26) or radical extirpation (n = 27) for primary female urethral cancer from 1948 through 1999.
  • Clinical stage, histology, high pathologic stage (3 or 4) and grade, tumor location, nodal status, surgery type, adjuvant therapy, and treatment decade were candidate outcome predictors.
  • For adjuvant therapy, 20 patients had radiation (8 preoperatively), 2 had radiation + chemotherapy, and 1 had chemotherapy alone.
  • During mean follow-up of 12.8 years, 27 patients had recurrence; 15 local only, 2 distant only and 10 local + distant.
  • Of patients undergoing partial urethrectomy for pT1-3 tumors, 6/27 (22%) had urethral recurrence.
  • Recurrence-free survival +/- standard error (SE) at 10 years was 45 + 8%.
  • Those who recurred had a cancer mortality rate of 71% at 5 years postrecurrence.
  • The estimated 10-year cancer-specific survival (CSS) and crude survival (CS) rates were 60 +/- 8% and 42 +/- 7%, respectively.
  • Pathologic stage was predictive for local recurrence (P = 0.02) and CSS (P = 0.01).
  • Positive nodes on pathology were related to local and distant recurrence and CSS (P = 0.01).
  • Upon review, partial urethrectomy resulted in a high urethral recurrence rate (22%) with no bladder recurrences.
  • [MeSH-major] Carcinoma / surgery. Neoplasm Recurrence, Local. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Humans. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Sex Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464921.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Liptak JM, Brutscher SP, Monnet E, Dernell WS, Twedt DC, Kazmierski KJ, Walter CU, Mullins MN, Larue SM, Withrow SJ: Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs. Vet Surg; 2004 Sep-Oct;33(5):505-16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transurethral resection in the management of urethral and prostatic neoplasia in 6 dogs.
  • OBJECTIVE: To assess cystoscopic transurethral resection (TUR) for the palliative management of dogs with neoplastic infiltration of the urethra.
  • METHODS: Cystoscopic examination and electrosurgical TUR were performed in dogs with urination difficulties caused by prostatic or urethral neoplasia.
  • Cystoscopic examination was used to determine the extent of neoplastic involvement of the urethra.
  • TUR involved piecemeal removal of neoplastic tissue from the urethral lumen using an electrocautery cutting loop.
  • In 2 male dogs, intraoperative radiation therapy (IORT) was used to treat both prostatic neoplasia and the sublumbar lymph node bed.
  • Surgical technique, complications, adjuvant treatment, and outcome were recorded.
  • RESULTS: TUR was performed in 3 male dogs with prostatic carcinoma and 2 female dogs with urethral transitional cell carcinoma (TCC).
  • Iatrogenic urethral perforation occurred during TUR in 3 dogs.
  • Treatment-related complications included urinary tract infection and tumor seeding.
  • Local tumor progression and metastasis occurred in all dogs.
  • CONCLUSIONS: TUR (in combination with chemotherapy+/-IORT) resulted in rapid palliation of urination difficulties in male dogs with prostatic carcinoma.
  • In female dogs with urethral TCC, however, electrosurgical TUR cannot be recommended because of a high intra- and postoperative complication rate with no improvement in postoperative management compared with historical reports of tube cystostomy.
  • In female dogs with urethral TCC, electrosurgical TUR does not provide any advantages compared with tube cystostomy.
  • [MeSH-major] Carcinoma, Transitional Cell / veterinary. Dog Diseases / surgery. Electrosurgery / veterinary. Prostatic Neoplasms / veterinary. Urethral Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15362989.001).
  • [ISSN] 0161-3499
  • [Journal-full-title] Veterinary surgery : VS
  • [ISO-abbreviation] Vet Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Leibovici D, Pagliaro L, Rosser CJ, Pisters LL: Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy. J Urol; 2005 Mar;173(3):781-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy.
  • PURPOSE: We report our experience with salvage radical surgery as palliative treatment in patients with bulky recurrence of prostate cancer following radical prostatectomy (RP).
  • MATERIALS AND METHODS: From files at the department of urology we identified 5 patients who had biopsy confirmed, bulky recurrence of prostate cancer after initial RP and subsequent salvage radiation therapy (4), prior to presentation at our cancer center.
  • All received androgen ablation and 4 also received systemic chemotherapy.
  • Total pelvic exenteration was done in 4 patients and wide tumor resection with continent urinary diversion was done in 1.
  • RESULTS: Four patients were permanently relieved of local symptoms following surgery and another had entero-urethral fistula formation.
  • Revision of a continent urinary diversion was necessary in another patient who was otherwise free of cancer and of local pelvic symptoms.
  • One patient died of metastatic disease 3.5 months after surgery but he had been rendered free of local symptoms by surgery.
  • The other 2 patients are currently free of local symptoms 5 and 7 months following surgery, respectively.
  • CONCLUSIONS: Salvage radical surgery is feasible and it provides effective palliation in patients with bulky local recurrence following RP.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Prostatectomy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Aged. Feasibility Studies. Humans. Male. Middle Aged. Salvage Therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711269.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


12. Sánchez-Ortiz R, Huang SF, Tamboli P, Prieto VG, Hester G, Pettaway CA: Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. J Urol; 2005 Jun;173(6):1958-65
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience.
  • We describe our experience with 10 patients with penile or urethral involvement.
  • RESULTS: Of 10 patients with penile or urethral melanoma 1997 American Joint Committee on Cancer melanoma pathological stage was T1 (depth less than 0.75 mm) in 4, T2 (0.75 to 1.5 mm) in 3 and T3 (1.51 to 4 mm) in 3.
  • In 7 patients with T1-2N0M0 disease there were no local recurrences after wide local excision (WLE) or partial penectomy at a median followup of 35 months.
  • One patient died of melanoma that developed at a second primary site.
  • Six patients with scrotal melanoma were treated with WLE without local recurrences.
  • Three of the 6 patients had palpable inguinal nodes, of whom 2 died after chemotherapy for unresectable disease and 1 died of other causes 51 months after negative BILND.
  • The 3 men with clinically negative groins who did not undergo prophylactic BILND had distant (1) or regional (2) metastases and died of disease.
  • CONCLUSIONS: Partial penectomy or WLE provided effective local control for low stage penile or urethral melanomas and all scrotal lesions.
  • Patients showing clinically positive, proven metastasis died despite appropriate surgical procedures and multi-agent chemotherapy.
  • Prophylactic modified inguinal lymphadenectomy should be considered in select patients with penile, scrotal and anterior urethral melanoma.
  • [MeSH-major] Genital Neoplasms, Male / surgery. Melanoma / surgery. Penile Neoplasms / surgery. Scrotum / surgery. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Urol. 2006 Apr;175(4):1574-5; author reply 1575-6 [16516049.001]
  • (PMID = 15879790.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Gschwend JE, Fair WR, Vieweg J: Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies. Eur Urol; 2000 Aug;38(2):121-30
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radical cystectomy for invasive bladder cancer: contemporary results and remaining controversies.
  • The impact of stage progression of superficial cancer to invasive disease is profound.
  • However, the optimal-timed management of invasive bladder cancer is still controversial.
  • Pelvic lymph node dissection and radical cystectomy are considered to be the optimal therapy regarding local tumor control and ultimate cure of cancer, whereas chemotherapy offers the only viable but limited option for patients with distant metastasis or locally advanced disease.
  • Identification of conventional and molecular prognostic factors to predict cancer-specific survival following radical cystectomy is one important step to identify candidates that may benefit from early cystectomy or adjunct chemotherapy.
  • [MeSH-minor] Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Neoplasms, Second Primary / epidemiology. Prognosis. Prostatic Neoplasms / pathology. Reproducibility of Results. Survival Rate. Urethral Neoplasms / surgery

  • Genetic Alliance. consumer health - Bladder cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895001.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] SWITZERLAND
  • [Number-of-references] 71
  •  go-up   go-down


14. Izawa JI, Perrotte P, Greene GF, Scott S, Levy L, McGuire E, Madsen L, von Eschenbach AC, Pisters LL: Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy. J Urol; 2001 Mar;165(3):867-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local tumor control with salvage cryotherapy for locally recurrent prostate cancer after external beam radiotherapy.
  • PURPOSE: We identified variables associated with a positive prostate biopsy after salvage cryotherapy in patients in whom initial external beam radiotherapy for prostate cancer failed to improve our cryotherapy technique, optimize local control and improve our patient selection criteria for salvage cryotherapy.
  • We evaluated certain variables on univariate and multivariate analysis as predictors of a positive biopsy after cryotherapy, including the type of previous therapy, tumor stage and grade at initial diagnosis, prostate volume, pre-cryotherapy prostate specific antigen (PSA), number of positive biopsy cores before cryotherapy, PSA nadir after cryotherapy, stage and grade of local recurrence, number of cryoprobes, number of freeze-thaw cycles and use of a urethral warming catheter during cryotherapy.
  • Variables associated with a positive biopsy on univariate analysis were initial stage, precryotherapy PSA, PSA nadir after cryotherapy, number of cryoprobes, number of freeze-thaw cycles and a history of chemotherapy (p = 0.005, 0.027, 0.001, 0.009, 0.018 and 0.008, respectively).
  • To optimize the potential for local control the technique of salvage cryotherapy should include 2 freeze-thaw cycles and a minimum of 5 cryoprobes.
  • Detectable PSA after salvage cryotherapy is a strong predictor of local failure.
  • [MeSH-major] Cryotherapy. Neoplasm Recurrence, Local / surgery. Prostatic Neoplasms / radiotherapy. Prostatic Neoplasms / surgery
  • [MeSH-minor] Biopsy. Humans. Male. Multivariate Analysis. Retrospective Studies. Salvage Therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11176488.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 16672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 19
  •  go-up   go-down


15. Edlich RF, Buschbacher RM, Cox MJ, Long WB, Winters KL, Becker DG: Strategies to reduce hyperthermia in ambulatory multiple sclerosis patients. J Long Term Eff Med Implants; 2004;14(6):467-79
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple sclerosis affects two to three times as many women as men.
  • On the basis of this positive hospital experience, hydrotherapy has been expanded through the use of compact aquatic exercise pools at home along with personal cooling devices that promote local and systemic hypothermia in multiple sclerosis patients.
  • In addition, products recommended for photoprotection by The Skin Cancer Foundation may also be helpful to the multiple sclerosis patient's defense against hyperthermia.
  • Infections in the urinary tract, especially detrusor-external sphincter dyssynergia, are initially managed conservatively with intermittent self-catheterization and pharmacologic therapy.
  • In those cases, refractory to conservative therapy, transurethral external sphincterotomy followed by condom catheter drainage is recommended.
  • However, if external urethral sphincterotomy fails to reduce residual urine and detrusor pressure, urinary diversion or bladder reconstruction may be necessary.
  • [MeSH-minor] Body Temperature / physiology. Female. Humans. Hydrotherapy / methods. Male. Protective Clothing. Risk Assessment. Sensitivity and Specificity. Severity of Illness Index. Sunscreening Agents / administration & dosage. Treatment Outcome. Walking

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Fever.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15698375.001).
  • [ISSN] 1050-6934
  • [Journal-full-title] Journal of long-term effects of medical implants
  • [ISO-abbreviation] J Long Term Eff Med Implants
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sunscreening Agents
  • [Number-of-references] 52
  •  go-up   go-down


16. Parekh DJ, Donat SM: Urinary diversion: options, patient selection, and outcomes. Semin Oncol; 2007 Apr;34(2):98-109
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Improved survival following radical cystectomy for bladder cancer as a result of advancements in combination chemotherapy and surgical technique has resulted in a philosophical change in the surgeon's approach to urinary diversion selection.
  • While quality of life is important, one must also consider the stage of cancer and individual patient comorbidities.
  • Which diversion provides the best local cancer control, the lowest potential for complications (short and long term), and the easiest emotional adjustment in lifestyle while still allowing the timely completion of chemotherapy and therapeutic goals?
  • We describe the three most commonly used types of diversions today, including conduits, continent cutaneous reservoirs, and orthotopic urethral diversions, as well as issues relative to patient selection and functional outcomes in patients undergoing radical cystectomy for the treatment of bladder cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382793.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


17. Place RJ, Gregorcyk SG, Huber PJ, Simmang CL: Outcome analysis of HIV-positive patients with anal squamous cell carcinoma. Dis Colon Rectum; 2001 Apr;44(4):506-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: With improved antiretroviral therapy, HIV-positive patients are achieving a longer life expectancy.
  • METHODS: We conducted a review based on our tumor registry from 1980 through 1999.
  • Data collected included age, CD4 count, treatment, complications, and survival; these data were analyzed by Student's t-test.
  • Those with squamous cell cancer of the anus were offered radiation therapy and chemotherapy.
  • Beginning in 1998, all patients received highly active antiretroviral therapy before treatment.
  • Seven of 14 anal squamous cell carcinoma patients had their therapy adjusted owing to toxicity.
  • Morbidity included proctocolitis and diarrhea (n = 2) requiring diversion (n = 1), hemorrhagic cystitis (n = 1), neutropenic fever (n = 3), bone marrow suppression (n = 1), and urethral stricture (n = 1).
  • In situ patients with CD4 counts as low as 105 cells/ml do well with local excision.
  • A low CD4 count at diagnosis without highly active antiretroviral therapy predicts a poor prognosis.
  • HIV-positive patients, particularly AIDS patients, with invasive anal cancers and without effective antiretroviral therapy obtain little benefit and significant toxicity from current radiation therapy and chemotherapy.
  • Initiation of highly active antiretroviral therapy in HIV-positive patients before radiation therapy and chemotherapy are begun may decrease toxicity and improve survival.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Combined Modality Therapy. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome


18. Giannarini G, Kessler TM, Thoeny HC, Nguyen DP, Meissner C, Studer UE: Do patients benefit from routine follow-up to detect recurrences after radical cystectomy and ileal orthotopic bladder substitution? Eur Urol; 2010 Oct;58(4):486-94
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of 479 patients with nonmetastatic bladder TCC receiving no neoadjuvant chemotherapy/radiation therapy and prospectively followed with a standardised protocol for a median 4.3 yr (range: 0.3-20.9) after RC at an academic tertiary referral centre.
  • MEASUREMENTS: Cancer-specific survival (CSS) and overall survival (OS) probability for asymptomatic and symptomatic recurrent patients were estimated using the Kaplan-Meier method.
  • The effects of age, nerve-sparing surgery, pathologic tumour stage, lymph node status, adjuvant chemotherapy, mode of recurrence diagnosis, and recurrence site on survival were assessed with multivariable Cox regression models.
  • Routine follow-up mostly detected lung metastases and urethral recurrences, while symptoms were predominantly the result of bone metastases and concomitant pelvic/distant recurrences.
  • Of 24 patients with urethral recurrences, 13 had carcinoma in situ (CIS).
  • Of these, 12 were successfully managed with urethra-sparing treatment, and 6 are still alive with no evidence of disease.
  • Routine follow-up appears particularly effective in early detection of urethral CIS, which can be treated conservatively.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Carcinoma, Transitional Cell / surgery. Cystectomy. Ileum / transplantation. Neoplasm Recurrence, Local / diagnosis. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / surgery. Urinary Reservoirs, Continent
  • [MeSH-minor] Aged. Early Detection of Cancer. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
  • [CommentIn] Eur Urol. 2010 Oct;58(4):495-7 [20609511.001]
  • (PMID = 20541311.001).
  • [ISSN] 1873-7560
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


19. Palou J, Baniel J, Klotz L, Wood D, Cookson M, Lerner S, Horie S, Schoenberg M, Angulo J, Bassi P: Urothelial carcinoma of the prostate. Urology; 2007 Jan;69(1 Suppl):50-61
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was conducted to explore the diagnosis and management of urothelial carcinoma of the prostate in superficial disease and carcinoma in situ, stromal invasion, primary urothelial carcinoma, and urethral recurrence after radical surgery.
  • Level 1 citations related only to chemotherapy and radiotherapy in patients with stromal invasion, although these were not related specifically to invasive prostatic involvement.
  • Published reports on the diagnosis and treatment of superficial urothelial disease of the prostate primarily consist of short case series from individual centers.
  • In invasive disease of the prostate, the only large series were designed to investigate invasive bladder cancer.
  • [MeSH-minor] Diagnosis, Differential. Global Health. Humans. Incidence. Male. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Prognosis. Prostatectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17280908.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 65
  •  go-up   go-down


20. Dalbagni G, Donat SM, Eschwège P, Herr HW, Zelefsky MJ: Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra. J Urol; 2001 Nov;166(5):1759-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of high dose rate brachytherapy, anterior pelvic exenteration and external beam radiotherapy for carcinoma of the female urethra.
  • PURPOSE: We evaluated a multimodality approach to locally advanced urethral carcinoma in women.
  • MATERIALS AND METHODS: Between August 1996 and July 1999, 6 women were treated for locally advanced carcinoma of the urethra with anterior pelvic exenteration followed by high dose 192iridium intraoperative radiation therapy.
  • Four of the 6 patients were also treated with neoadjuvant or concomitant platinum based chemotherapy.
  • RESULTS: Two patients had no evidence of disease, 3 had distant metastasis and 2 had local recurrence at a mean followup of 21 months (range 12 to 47).
  • Local control seems to have improved.
  • We must evaluate a larger cohort of patients to determine this impact of the combined modality on local control and patient survival.
  • [MeSH-major] Brachytherapy. Carcinoma, Transitional Cell / radiotherapy. Carcinoma, Transitional Cell / surgery. Pelvic Exenteration. Urethral Neoplasms / radiotherapy. Urethral Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Humans. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11586218.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Ramyil VM, Dakum NK, Liman HU, Udeh EI: The management of prostatic haematuria. Niger J Med; 2008 Oct-Dec;17(4):439-42
MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report, we have reviewed the incidence, precipitating/co morbid factors, treatment and outcome of haematuria in patients with benign prostatic hyperplasia and prostate cancer METHODS: A two year prospective review of 37 patients who presented with haematuria associated with benign prostatic hyperplasia and prostate cancer Each patient had full clinical assessment, including any associated precipitating or co morbid factors.
  • All patients had urethral catheterization; and cystoscopy to exclude bladder tumours or bladder stones.
  • Upon stabilization, the definitive treatment in each patient was based on primary pathology.
  • RESULTS: A total of 134 patients who had either benign prostatic hyperplasia or prostate cancer were treated.
  • The incidences of haematuria in benign prostatic hyperplasia and prostate cancer were 26.7% and 29.2% respectively.
  • In most cases conservative management is the key In the absence of modern facilities, emergency open prostatectomy may be needed to control bleeding, in those in whom conservative approach has failed; or when specifically indicated based on the individual patient or as dictated by other local factors.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Health Status Indicators. Humans. Incidence. Male. Middle Aged. Prospective Studies. Prostatic Neoplasms / complications. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / drug therapy. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19048763.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


22. Chen Q, Huang Z, Luck D, Beckers J, Brun PH, Wilson BC, Scherz A, Salomon Y, Hetzel FW: Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers. Photochem Photobiol; 2002 Oct;76(4):438-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
  • Photodynamic therapy (PDT) uses light to activate a photosensitizer to achieve localized tumor control.
  • In this study, PDT mediated by a second-generation photosensitizer, palladium-bacteriopheophorbide WST09 (Tookad) was investigated as an alternative therapy for prostate cancer.
  • PDT was performed by irradiating the surgically exposed prostate superficially or interstitially at 763 nm to different total fluences (100 or 200 J/cm2; 50, 100 or 200 J/cm) at 5 or 15 min after intravenous administration of the drug (2 mg/kg).
  • The local light fluence rate and temperature were monitored by interstitial probes in the prostate.
  • All animals recovered well, without urethral complications.
  • During the 1 week to 3 month post-treatment period, the prostates were harvested for histopathological examination.
  • The PDT-induced lesions showed uniform hemorrhagic necrosis and atrophy, were well delineated from the adjacent normal tissue and increased linearly in diameter with the logarithm of the delivered light fluence.
  • A maximum PDT-induced lesion size of over 3 cm diameter could be achieved with a single interstitial treatment.
  • At therapeutic PDT levels, there was no structural or functional urethral damage even when the urethra was within the treated region.
  • Hence, Tookad-PDT appears to be a promising candidate for prostate ablation in patients with recurrent, or possibly even primary, prostate cancer.
  • [MeSH-major] Bacteriochlorophylls / pharmacology. Photochemotherapy. Photosensitizing Agents / pharmacology. Prostate / drug effects. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12405153.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA43892
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacteriochlorophylls; 0 / Photosensitizing Agents; 0 / palladium-bacteriopheophorbide
  •  go-up   go-down


23. Nag S, Tippin D, Ruymann FB: Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors: the Ohio State University experience. Int J Radiat Oncol Biol Phys; 2001 Nov 1;51(3):729-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative high-dose-rate brachytherapy for the treatment of pediatric tumors: the Ohio State University experience.
  • PURPOSE: To determine whether intraoperative high-dose-rate brachytherapy (IO-HDRBT) can be used to decrease the dose of external beam radiotherapy (EBRT) in the treatment of children with soft-tissue sarcomas and, thereby, reduce morbidity without compromising local control.
  • METHODS AND MATERIALS: From March 1992 through April 1999, 13 pediatric patients were treated with IO-HDRBT, low-dose EBRT, chemotherapy, and radical surgery at 21 sites that were not amenable to intraoperative electron beam therapy.
  • The IO-HDRBT dose at 5 mm depth was 10 to 12.5 Gy for close margins/microscopic disease at 14 sites and 12.5 to 15 Gy for gross disease at 7 sites.
  • The treatment volumes ranged from 4 to 96 cm(3) (mean 27).
  • The EBRT dose was limited to 27-30 Gy in most cases to minimize growth retardation and preserve normal organ function.
  • One local failure occurred in a patient with gross residual disease after incomplete resection for Stage IV pulmonary blastoma.
  • The local control rate was 95%, and morbidity was observed in 3 patients (23%).
  • One patient developed impaired orbital growth with mild ptosis.
  • Another patient required orthopedic pinning of her femoral subcapital epiphysis and construction of a neobladder secondary to urethral obstruction.
  • CONCLUSIONS: IO-HDRBT allowed for reduction in EBRT without compromising local control or disease-free survival in children with soft-tissue sarcomas.
  • Tumor beds inaccessible to electron beam methods could be satisfactorily encompassed with IO-HDRBT techniques.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Intraoperative Period. Male. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11597815.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Matos T, Cufer T, Cervek J, Bornstnar S, Kragelj B, Zumer-Pregelj M: Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):403-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The results of bladder sparing approach for the treatment of muscle-invasive bladder cancer, using a combination of transurethral resection (TUR), chemotherapy, and radiotherapy, are encouraging.
  • The aim of our study was to find out which pretreatment characteristics influence the survival of patients treated by organ sparing approach that would enable us to identify the patients most suitable for this type of treatment.
  • METHODS AND MATERIALS: The prognostic value of different factors, such as age, gender, performance status, hemoglobin level, clinical stage, histologic grade, presence of obstructive uropathy, and completeness of TUR, has been studied in 105 patients with invasive bladder cancer, who received a bladder sparing treatment in the period from 1988 to 1995.
  • In complete responders the treatment was completed by radiotherapy (50 Gy to the bladder and 40 Gy to the regional lymph nodes), whereas nonresponders underwent cystectomy whenever feasible.
  • RESULTS: Our study has confirmed an independent prognostic value of performance status, histologic grade, and obstructive uropathy, for the disease-specific survival (DSS) of bladder cancer patients treated by a conservative approach.
  • We believe that performance status best reflects the extent of disease and exerts significant influence on the extent and course of treatment, while obstructive uropathy is a good indicator of local spread of the disease, better than clinical T-stage.
  • Our finding that histologic grade is one of the strongest prognostic factors shows that tumor biology also is a very important prognostic factor in patients treated by conservative approach.
  • CONCLUSION: Patients with muscle-invasive bladder cancer who are most likely to benefit from conservative treatment approach include those with good performance status, absence of hydronephrosis, and histologic low grade transitional cell carcinoma.
  • [MeSH-major] Carcinoma, Transitional Cell / therapy. Urinary Bladder Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / blood. Carcinoma / pathology. Carcinoma / therapy. Combined Modality Therapy. Female. Follow-Up Studies. Hemoglobin A / analysis. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Severity of Illness Index. Sex Factors. Urethral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661347.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 9034-51-9 / Hemoglobin A
  •  go-up   go-down


25. Potempal AJ, Potempa DM, Görlich HD, Stolpmann RM: [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)]. Arzneimittelforschung; 2007;57(6):299-308
Hazardous Substances Data Bank. APOMORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
  • [Transliterated title] Intraurethral zu applizierendes Alprostadil zur Behandlung der primär organisch bedingten Erektilen Dysfunktion in der Praxis.
  • In a multicenter clinical monitoring study (observation of use investigation according to 67.6 of the German Drug Law), which was conducted between 2003 and 2005 in 105 urological practices in 314 patients with organic erectile dysfunction (ED), efficacy, safety, convenience and acceptance of intraurethral administered alprostadil (CAS 745-65-3; MUSE - Medicated Urethral System for Erection) was studied.
  • The time of ED was from 2 to 120 months with a mean duration of 21.5 +/- 22 months (median+/-SD.
  • Genesis of the ED was in 55 % of the patients a local damage, which followed in 42.8 % a prostate cancer surgery.
  • In 51.3% of the patients drugs, which were known to induce ED, were suspected to have caused or partially caused the impairment.
  • Alprostadil (MUSE) was applicated three times in doses of 250, 500 or 1000 microg.
  • In patients after surgery because of prostate cancer very good and good efficacy improved in comparison to the first application about 20% and concerned 53.9 % of the patients after the third application.
  • 81.1% intended to continue the treatment.
  • In a retrospective comparison with other drugs for the treatment of ED intracavernosal alprostadil ("SKAT") was slightly more effective than intraurethral alprostadil (MUSE) (32.1% vs 25 %), but alprostadil (MUSE) was assessed more useful by 82.1% and preferred by 78.6% of the patients.
  • Five adverse events were reported (slight urethral pain).
  • In this non-interventional investigation the good efficacy and tolerability of intraurethral applicated alprostadil (MUSE) as a second-line therapy after failure or minor efficacy of PDE-5 inhibitors and other oral drugs was comparable with the results of the clinical trials.
  • [MeSH-major] Alprostadil / therapeutic use. Erectile Dysfunction / drug therapy. Vasodilator Agents / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Apomorphine / therapeutic use. Body Mass Index. Dopamine Agonists / therapeutic use. Double-Blind Method. Drug Therapy, Combination. Humans. Injections. Male. Middle Aged. Orgasm / drug effects. Penile Erection / drug effects. Phosphodiesterase Inhibitors / therapeutic use. Postoperative Complications / drug therapy. Quality of Life. Urethra

  • Genetic Alliance. consumer health - Erectile Dysfunction.
  • MedlinePlus Health Information. consumer health - Erectile Dysfunction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17688074.001).
  • [ISSN] 0004-4172
  • [Journal-full-title] Arzneimittel-Forschung
  • [ISO-abbreviation] Arzneimittelforschung
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Phosphodiesterase Inhibitors; 0 / Vasodilator Agents; F5TD010360 / Alprostadil; N21FAR7B4S / Apomorphine
  •  go-up   go-down






Advertisement